Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Barchart · 06/25 06:05

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474

In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.